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Inherited muscle disorders are caused by pathogenic changes in numerous genes. Herein, we aimed to investigate
the etiology of muscle disease in 24 consecutive Greek patients with myopathy suspected to be genetic in origin,
based on clinical presentation and laboratory and electrophysiological findings and absence of known acquired
causes of myopathy. Of these, 16 patients (8 females, median 24 years-old, range 7 to 67 years-old) were
diagnosed by Whole Exome Sequencing as suffering from a specific type of inherited muscle disorder. Specif
ically, we have identified causative variants in 6 limb-girdle muscular dystrophy genes (6 patients; ANO5,
CAPN3, DYSF, ISPD, LAMA2, SGCA), 3 metabolic myopathy genes (4 patients; CPT2, ETFDH, GAA), 1 congenital
myotonia gene (1 patient; CLCN1), 1 mitochondrial myopathy gene (1 patient; MT-TE) and 3 other myopathyassociated genes (4 patients; CAV3, LMNA, MYOT). In 6 additional family members affected by myopathy, we
reached genetic diagnosis following identification of a causative variant in an index patient. In our patients,
genetic diagnosis ended a lengthy diagnostic process and, in the case of Multiple acyl-CoA dehydrogenase
deficiency and Pompe’s disease, it enabled specific treatment to be initiated. These results further expand the
genotypic and phenotypic spectrum of inherited myopathies.

1. Introduction
Inherited muscle diseases are a heterogeneous group of disorders, that
includes congenital, metabolic and mitochondrial myopathies, muscular
dystrophies and myotonias [1,2]. Each of these categories of genetic
muscle disorders is in turn broad, with muscular dystrophies subdivided to
Duchenne/Becker, myotonic, facioscapulohumeral, distal and limb-girdle
muscular dystrophies (LGMD) [1]. This predominantly phenotype-based
classification has been adequate for several decades; however, it has

become obsolete after the delineation of the genetic and molecular basis of
most of these disorders in recent years. These advances have led to the
realization that defects in a certain gene can cause various myopathic
phenotypes, and inversely, the same phenotype can be caused by different
pathogenic variants in the same or multiple genes (allelic and locus het
erogeneity) [3]. For instance, LGMDs, characterized by weakness affecting
predominantly the shoulder and pelvic girdle muscles, are caused by
pathogenic changes in more than 30 genes, with the gene altered and the
mode of inheritance determining the LGMD subtype[4–12].
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Clinical and other characteristics, such as the precise distribution of
muscle weakness or the levels of serum creatine phosphokinase (CPK)
have been associated with specific inherited myopathy subtypes. How
ever, predicting the genetic defect involved in a myopathy based on the
history, clinical features, MRI findings and muscle biopsy results is
practically impossible [9]. Furthermore, there is significant clinical and
genetic overlap among various inherited muscle disorders. For instance,
LGMDs phenotypically and genotypically overlap with other types of
muscular dystrophies, such as the Congenital Muscular Dystrophies
[13,14].
Next generation sequencing (NGS) techniques, such as Targeted
Gene Panels and Whole Exome Sequencing (WES), have revolutionized
the diagnostic process of inherited myopathies [4,7,15–19]. Compared
with other, gene-panel based, NGS techniques, WES provides a nonbiased approach towards the identification of established pathogenic
variants and the discovery of novel variants and genes associated with
heterogeneous disorders, such as myopathies [20]. This improved
diagnostic efficacy through high-throughput genetic testing is a pre
requisite for management decisions, prognostication, and genetic
counseling for patients with inherited myopathies.
Here, using WES, we expand further the phenotypic and genotypic
spectrum of inherited muscle diseases, by establishing the genetic eti
ology of myopathy in 16 patients from Greece and 6 of their family
members. In this cohort of unselected patients, referred to us from
neurologists and pediatric neurologists across Greece, we have identi
fied causative variants, including some novel ones, in 14 inherited
myopathy genes (ANO5, CAPN3, CAV3, CLCN1, CPT2, DYSF, ETFDH,
GAA, ISPD, LAMA2, LMNA, MYOT, MT-TE and SGCA).

2.3. Whole exome sequencing
WES and initial bioinformatics analysis were performed in a CLIAcertified laboratory (Otogenetics Corporation, Norcross, GA, USA).
Exome library preparation was performed using the Agilent V5 (51Mb)
Sure-Select Target Enrichment System. Exon-enriched DNA libraries
were sequenced on a HiSeq 2000/2500 (Illumina, USA) platform using
paired end reads of 100-125 bp with an estimated average coverage of
50X. The data were then processed using the DNA Nexus platform,
consisting of alignment of reads for each patient to the human reference
genome hg19/GRCh37, removal of PCR duplicates using Picard, indel
realignment and base quality score recalibration, variant calling and
quality evaluation using the Genome Analysis ToolKit version 3.6. On
average, the percentage of nucleotides with at least 50x coverage was
more than 60%, and the average depth of coverage per interval was over
60. Sequencing results were transmitted through the DNAnexus.com
platform (Mountain View, CA, USA).
2.4. WES data analysis
Annotation of called variants was performed at the Neurogenetics
Laboratory, University of Crete through a combined approach using the
automated Ingenuity Variant Analysis (IVA, Qiagen, USA) and
GenomeTrax 2015.1 (Biobase, Wolfenbüttel, Germany) software, fol
lowed by semi-automated annotation of variants, integrating informa
tion from online databases (i.e. ClinVarTM, HGMD®), other
bioinformatics tools and literature sources. The semi-automatic curation
of variants was performed using stepwise filtering, to generate a list of
possible disease-associated variants. Ascertainment was based on fea
tures of both the gene (e.g. inheritance patterns, functional evidence)
and the specific variant (e.g. location, type, population frequency,
computational predictions of effect). We therefore excluded variants
with minor allele frequency > 1% on databases such as the Exome Ag
gregation Consortium (ExAC) dataset and focused on variants which
produced a missense, non-sense, frameshift or splicing change. We also
kept all potentially pathogenic genetic variants listed in the Human
Gene Mutation Database (HGMD®). The functional consequences of
identified variants on encoded proteins were also assessed using the
VarSome database (https://varsome.com) that compiles prediction
scores from several prediction algorithms including SIFT, PROVEAN,
MutationTaster, PhyloP, FATHMM, and MetaSVM [21]. The Combined
Annotation Dependent Depletion (CADD) score was also taken into
consideration to ascribe pathogenicity to given variants [22]. Final
interpretation of the pathogenicity of identified variants was performed
manually taking into consideration data available in public databases
and published in the literature. The classification of variants followed
the recommendations by the American College of Medical Genetics and
the Association for Molecular Pathology Laboratory Practice Committee
Working Groups [23].

2. Patients and methods
2.1. Study subjects
The study group included 24 consecutive patients with suspected
genetically determined myopathy, based on the clinical presentation,
electrophysiological studies, and absence of known acquired causes of
myopathy. Also, patients with a complex phenotype where myopathy
was not a prominent feature were excluded. For 16 of the 24 patients
included in the study, the genetic cause of myopathy was identified via
WES in the Neurology/Neurogenetics Laboratory, Medical School,
University of Crete and are described herein. For 8 of the 24 patients (3
males, 5 females), including 5 patients with LGMD type of weakness, 2
patients with congenital myopathy, and 1 patient with prominent
rhabdomyolysis and quadriceps weakness, we were not able to reach a
specific genetic diagnosis. For these patients, the median age at testing
was 19.5 years (range 4-72) and the median age at symptom onset 15
years (0-52). There were no major phenotypic differences between pa
tients for whom a genetic diagnosis was reached and those for whom the
cause of their myopathy remained unresolved, with the exception of
presence of 2 patients with congenital myopathy in the latter group.
Informed consent for performing clinical WES was obtained from the
patients and/or their legal guardians. The study protocol was performed
following the ethical guidelines of the World Medical Association
Declaration of Helsinki (version 2008) and was also approved by the
Institutional Review Board of the University Hospital of Heraklion,
Crete, Greece.

2.5. Sanger sequencing and MLPA analyses
Variants related to patient phenotypes were confirmed by Sanger
sequencing for the patients, parents and affected relatives, if applicable,
either at the Neurology Laboratory, University of Crete or at Diagenom
(Rostock, Germany). MLPA analysis, needed to search for a trans variant
in patient #2 with a single variant identified via WES, were performed at
Diagenom (Rostock, Germany).

2.2. Blood sampling and DNA extraction
Peripheral blood (~5ml) was collected in ethylene diamine tetraacetic acid (EDTA) tubes and stored at − 80 ◦ C until use. DNA was
extracted from 1mL of whole blood, using the QIAamp DNA blood midi
kit (Qiagen, USA) following the manufacturer’s centrifugation-based
protocol. DNA concentration and purity were determined spectropho
tometrically by absorbance measurement at 260 and 280 nm and
agarose electrophoresis.

3. Results/case descriptions (Tables 1, 2)
3.1. Patient #1 (АNΟ5)
This 16-year-old male patient presented easy fatigability, mainly of
the lower extremities, since about two years and showed increased CPK
(up to 1,200 U/L) on several occasions. Via WES, he was found to be
2

I. Zaganas et al.

Molecular Genetics and Metabolism Reports 25 (2020) 100682

Table 1
Demographic, clinical and laboratory features of the inherited muscle disorder cases identified through whole exome sequencing (WES).
Patient
#

Sex

Age at
diagnosis
(y)

Age at
onset

Clinical features

Family history

NCS/EMG features

Muscle biopsy/Labs (CPK)

1

M

16

14

-

-

Elevated CPK

2

M

34

16

Affected brother

-

Elevated CPK

3

F

45

40

-

-

-

4
5

F
F

29
14

10
13

Mild lower extremity weakness, easy
fatigability
Central-type muscle weakness, abolished
tendon reflexes
Myopathy (exercise induced muscle stiffness
and myalgias, moderate proximal muscle
weakness)
No cardiomyopathy
Myotonic symptoms
Myalgias

Myotonia
-

Elevated CPK

6
7
8

M
M
F

17
19
7

14
7
2

Myalgias
Pain and cramps in legs
Lower extremity weakness, easy fatigability

Affected sister
Affected sister, father,
paternal siblings
Affected sister
-

Myopathy
Myopathy

9

F

67

57

Central type muscle weakness, respiratory
difficulties

-

Myopathy

10

F

19

10

Affected sister

Мyopathy

11
12
13

M
F
F

38
39
47

1
Childhood
35

Scapular winging, tibial hypertrophy, scoliosis,
waddling gait, central type muscle weakness,
respiratory dysfunction, decreased tendon
reflexes
Progressive muscle weakness
Myopathy, cardiomyopathy
Myopathy, cardiomyopathy

Elevated CPK
Elevated CPK, transaminases
Muscle biopsy: lipid
myopathy
Muscle biopsy nondiagnostic / DBS, cultured
fibroblasts low GAA activity
Elevated CPK

-

Elevated CPK
Elevated CPK
-

14

М

17

3

Progressive muscle weakness, glucose
intolerance

-

Elevated CPK

15

M

54

53

Proximal weakness, atrophy in the shoulder
girdle and the face

Elevated CPK

16

М

12

5

Tested for increased CPK values

Myopathy with
face-shoulder-arm
distribution
-

De novo
Possibly affected
father and sibling
(sudden deaths)
Affected mother with
myopathy, diabetes in
family
Son: cardiac
defibrillator at the age
of 14 years
-

Elevated CPK

3.3. Patient #3 (CAV3)

heterozygous for the p.Phe506fs*6 (c.1517delT) and p.Met542fs*11
(c.1624dupA) changes in the ANO5 gene, as a cause of LGMD type R12
(formerly 2L). Both variants lead to a shift in the reading frame and a
truncated protein product. Moreover, both p.Phe506fs*6 and p.
Met542fs*11 are characterized as deleterious according to CADD (scores
of 23.1 and 35.0, respectively; Table 2).

This 44-year-old female patient presented with a history of exerciseinduced muscle stiffness and myalgias, symptoms that developed since
early adulthood and had been initially misdiagnosed as fibromyalgia.
She developed progressive proximal muscle weakness, mainly in the
pelvic area and the lower limbs. There was no family history of myop
athy. Biochemical testing, CPK and inflammatory markers were normal.
The patient underwent muscle biopsy that produced no specific findings,
whereas only the latest of a series of EMGs revealed mild myopathic
findings. The ECG, heart U/S and investigation for glycogen storage
disorders produced normal results. Via WES we found that the patient
carried the previously described as pathogenic p.Thr78Met (c.233C>T)
CAV3 variant, in the heterozygous state, as a cause of caveolinopathy
(formerly known as LGMD-1C). The unaffected father was also hetero
zygous for the same variant.

3.2. Patient #2 (CAPN3)
This 34-year-old man presented with progressive proximal weakness
and atrophies of the upper and lower extremities since the age of 16
years (Fig. 1). On examination, tendon reflexes were abolished, except
for the Achilles tendon reflexes. Serum testing revealed repeatedly
elevated CPK values. The patient’s brother, but not his sister, had a
similar clinical picture, with proximal muscle weakness in all four limbs
since the age of 10 years. Based on the clinical picture of both brothers
and the absence of myopathy in the sister, an X-linked inheritance was
initially suspected. However, both the patient and his brother tested
negative for DMD gene pathogenic changes. WES in the patient identi
fied the p.Tyr537* (c.1611C>A) change in the CAPN3 gene in a het
erozygous state. Further testing of the CAPN3 gene by MLPA showed an
additional heterozygous deletion of exons 2 to 8 (c.310-?_c.1115+?del)
which leads to the p.Glu104_Arg372delfshX11 amino acid change
causing a frameshift and a new stop codon located 11 codons down
stream. By testing the father of the patient, who harbored only the
heterozygous deletion of exons 2 to 8, we established that the patho
genic variants in the patient were in a trans state. Thus, we reached the
diagnosis of LGMD type R1 (previous classification, 2A).

3.4. Patient #4 (CLCN1)
This 29-year-old patient has been experiencing myotonic symptoms,
especially in the lower extremities, since the age of 10 years. These
symptoms appeared at the initiation of movement, as in standing up
from a seating position or climbing stairs. EMG studies in the patient and
her affected sister, but not in her clinically unaffected mother, showed
myotonic activity. Testing by WES established the diagnosis of Myotonia
Congenita due to the exonic p.Phe167Leu (c.501C>G) and splice site
c.1471+1G>A variants in the CLCN1 gene. These changes were verified
by Sanger sequencing and were also found in her similarly affected
sister.
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Table 2
Characteristics of the variants identified through whole exome sequencing (WES) in our cohort.
Patient
#

Gene

Variants

CADD
score

ID

gnomAD
frequency
(%)

rs

Pathogenicity
Criteria (ACMG)*

Phenotype

p.Phe506fs*6 (c.1517delT)
/
p.Met542fs*11 (c.1624dupA)

23.1
/
35.0

NM_01142649.2

0.000
/
0.004

794727158
/
281865480

PVS1, PS4, PM2,
PM3
/
PVS1, PS4, PM2,
PM3
PVS1, PS3, PS4,
PM2, PM3
/
PM3, PM4
PS3, PS4, PM1,
PM5, PP3,
BS1, BP5, BP6
PS4, PM1, PM2,
PM3,
PP1, PP5, BP6
/
PVS1, PS3, PS4,
PM2, PM3, BS2
PA2, PS3, PS4,
PM3,
PP3, PP5, BS1,
BS2
PVS1, PM2
/
PVS1, PS4, PM2,
PM3, PP5
PS4, PM2, PM3,
PP3, PP5
/
PVS1, PS4, PM2
PA2, PS3, PS4,
PM3, PP5,
BS1, BS4, BP2,
BP4
/
PS3, PS4, PM1,
PM2,
PM3, PP3, PP5

LGMD R12
(former 2L)

1

АNΟ5

2

CAPN3

p.Tyr537* (c.1611C>A)
/
deletion of exons 2 to 8 (c.310-?_c.1115+?del)

38.0
/
-

NM_000070.3

0.000
/
0.000

886042439
/
-

3

CAV3

p.Thr78Met (c.233C>T)

23.0

NM_001234.5

0.270

72546668

4

CLCN1

p.Phe167Leu (c.501C>G)
/
c.1471+1G>A

20.3
/
34.0

NM_000083.3

0.110
/
0.002

149729531
/
375596425

5,6

CPT2

p.Ser113Leu (c.338C>T)
-Homozygous

34.0

NM_000098.3

0.140

74315294

7

DYSF

c.997-1G>A
/
p.Ala927fs*21 (c.2779delG)

33.0
/
35.0

NM_003494.4

0.000
/
0.002

/
727503909

8

ETFDH

p.Pro483Leu (c.1448C>T)
/
p.Arg559* (c.1675C>T)

27.4
/
42.0

NM_04453.4

0.002
/
0.000

377656387
/
186023896

9

GAA

c.32-13T>G
/
p.Tyr292Cys (c.875A>G)

<10
/
28.5

NM_000152.5

0.340
/
0.001

NM_01101426.4

0.000

10

CRPPA
(ISPD)

p.Thr238Ala (c.712A> G)
-Homozygous

24.9

11

LAMA2

12

LMNA

c.2208+4_2208+19delAGCTTGCAAGAATGTA
/
p.Ile2508fs*4 (c.7521dupT)
p.Arg249Gln (c.746G>A)

/
27.1

13

LMNA

c.1608+2T>C

14

MT-TE

15
16

*

386834236
/
1057516600

1038301242

NM_170707.4

0.000
/
0.000
0.000

/
59332535

29.4

NM_170707.4

0.000

-

PS4, PM1, PM2,
PM5, PP3
PM2
/
PVS1, PM2
PS4, PM1, PM2,
PM6,
PP3, PP5, BP2
PVS1, PM2

m.14709T>C

<10

NC_012920.1

-

121434453

BP4

MYOT

p.Thr57fs*2 (c.170delC)

33.0

NM_006790.3

0.000

-

PVS1, PM2

SGCA

p.Val247Met (c.739G>A)
/
p.Arg284Cys (c.850C>T)

25.8
/
33.0

NM_000023.4

143570936
/
137852623

PS3, PS4, PM1,
PM2,
PM3, PP1, PP3,
PP5
/
PS3, PS4, PM1,
PM2,
PM3, PP3, PP5

NM_000426.4

0.010
/
0.020

LGMD R1
(former 2A)
Caveolinopathy
(former LGMD
1C)
Myotonia
Congenita

Metabolic
Myopathy
LGMD R2
(former 2B)
Metabolic
Myopathy
Metabolic
Myopathy
(former LGMD
2V)

LGMD R20
LGMD R23
Laminopathy
(former LGMD
1B)
Laminopathy
(former LGMD
1B)
Mitochondrial
Myopathy
Myotilinopathy
(former LGMD
1A)
LGMD R3
(former 2D)

Criteria according to Richards et al, Genet Med, 2015 (Standards and Guidelines for the Interpretation of Sequence Variants) through the Ingenuity software.

3.5. Patient #5 (CPT2)

myalgias and increased CPK since the age of 4 years. Myalgias were also
reported in the father of the two sisters, as well as in 2 paternal uncles.
Testing by WES followed by Sanger sequencing established the diagnosis
of CPT II deficiency due to the homozygous p.Ser113Leu (c.338C>T)
CPT2 variant in the patient and her similarly affected sister. The variant
has been identified in 0.2% (134/66568) of European chromosomes by
the Exome Aggregation Consortium (ExAC, http://exac.broadin stitute.

This 14-year-old patient presented with episodes of myalgia and
rhabdomyolysis since at least one year, with increased CPK (up to 7,355
U/L) found on several occasions. Testing for both organic acids and
carnitine esters, even when the patient had significantly elevated CPK
levels, gave normal results. Her 12-year-old sister had episodes of
4
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Fig. 1. Photos of the upper extremities of patient #2, showing marked atrophy of the proximal muscles and scapular winging. This patient and his similarly affected
brother were found to harbor both the p.Tyr537* change and the deletion of exons 2 to 8 in the CAPN3 gene in compound heterozygosity.

derangement of lipid metabolism (lipid storage myopathy). VLCAD
measurements in fibroblasts produced normal results. Testing by WES
established the diagnosis of metabolic myopathy due to the p.Pro483Leu
(c.1448C>T) and p.Arg559* (c.1675C>T) changes in the ETFDH gene.
The latter is highly deleterious (CADD=42.0) and causes premature
translation termination resulting in a truncated protein. Sanger
sequencing verified the presence of these variants in the patient and
testing of the parents and the unaffected brother showed that these two
variants were in trans. This allowed the initiation of specific therapy
with riboflavin, with significant improvement in muscle strength and
exercise endurance already noted in the first few months of treatment.

org; dbSNP rs74315294).
3.6. Patient #6 (CPT2)
This 17-year-old patient has presented severe rhabdomyolysis after a
viral upper respiratory tract infection. Three years earlier he had been
hospitalized because of severe rhabdomyolysis and acute renal failure,
necessitating temporary renal dialysis, that had been attributed to
salmonellosis. He had repeatedly increased CPK values, up to 200,000
U/L. Testing for organic acids and carnitine esters, on repeated occa
sions, gave results within normal range. In this patient, WES established
the diagnosis of CPT II deficiency due to the homozygous p.Ser113Leu
(c.338C>T) CPT2 gene variant. The latter was verified by Sanger
sequencing and found in homozygous and heterozygous state in the
patient’s sister and brother, respectively. He was apparently unrelated
to patient #5, even though they both carried the same p.Ser113Leu
CPT2 change. Following genetic diagnosis, both the patient and his
similarly affected sister followed special nutrition directions and avoi
ded strenuous exercise.

3.9. Patient #9 (GAA)
This 67-year-old woman presented with a 10-year history of pro
gressive difficulties in climbing stairs, getting up from sitting position
and walking, as well as orthopnea. On neurological examination,
proximal muscle weakness was noted in all four extremities; the patient
was walking with a cane. Pulmonary function studies showed reduced
Forced Vital Capacity-FVC (49% of predicted). CPK levels were mildly
elevated (160-200 U/L), while EMG showed non-specific myopathic
changes. Muscle biopsy was non diagnostic, since it revealed vacuolar
myopathy, ragged-red, moth-eaten fibers and absence of glycogen
accumulation. WES revealed heterozygosity for two GAA gene patho
genic variants, one in intron 1 (c.-32-13T>G) and one in exon 5 (p.
Tyr292Cys, c.875A>G). These were confirmed by Sanger sequencing,
while genotyping the patient’s mother confirmed compound heterozy
gosity in the patient. An initial dried blood spot (DBS) GAA enzyme
assay showed normal activity. Repeated testing showed abnormally low
GAA activity in DBS (1.13 pmoles/punch/hr; normal range: 5.3-31.5)
and fibroblasts (0.23 nmoles/mg/min; normal range: 0.34-4.9). Thus,
the diagnosis of Pompe’s disease was confirmed and substitution ther
apy was initiated. This led to an initial improvement in motor scores
(mean 14.5m increase on the 6-minute walk test) and pulmonary
function studies. However, the patient developed a severe lower respi
ratory tract infection and passed away 3 years after the initial genetic
diagnosis.

3.7. Patient #7 (DYSF)
This 18-year-old male presented with progressive weakness, pain
and cramps in both lower extremities. At the age of 7 years, testing for
growth hormone deficiency, due to mild delay in growth, showed no
abnormal findings. At the age of 8 years, laboratory testing revealed
increased CPK values, with progressive increase in the ensuing years
(peak value of about 23,000 U/L). Testing for Pompe disease was
negative. Neurophysiological testing, performed in 2006 and repeated
in 2014, showed myopathic features, with recording of spontaneous
activity (fibrillation potentials and positive sharp waves) and early
recruitment of motor units. A muscle biopsy, performed in 2007, showed
no abnormal findings. Genetic testing for muscular dystrophy by
sequencing and MLPA analysis of the DMD gene did not reveal any
pathogenic changes. By using WES, we found that the patient was a
compound heterozygote for the pathogenic c.907-1G>A and p.
Ala927fs*21 (c.2779delG) changes in the DYSF gene. The former is a
novel variant predicted to affect splicing and characterized by strong
computational support for pathogenicity (CADD score = 33.0). The
latter is present in population databases (rs745407251, ExAC 0.02%),
but is associated mainly with LGMD-R2 pathogenicity and causes
frameshift and premature termination of the protein translation.

3.10. Patient #10 (CRPPA-ISPD)
This 19-year-old female had experienced progressive muscle weak
ness and walking difficulties in the past 9 years. On clinical examination,
scapular winging, calf hypertrophy, scoliosis, wadding gait, muscular
weakness in a limb-girdle distribution, impaired respiratory function
(FVC at 65% of normal values) and markedly decreased deep tendon
reflexes were noted. Serum CPK levels were persistently elevated (8–10X
normal values). Repeated EMG studies were suggestive of myopathy. At
the age of 14 years, she underwent muscle biopsy, where immune-

3.8. Patient #8 (ETFDH)
This 7-year-old female patient presented lower and upper extremity
weakness and easy fatigability since the age of 2 years. Muscle biopsy at
the time showed findings compatible with metabolic myopathy due to
5
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reactivity to antibodies against dystrophin (DYS-1, DYS-2, DYS-3) and β,
γ and δ sarcoglycan, but not against caveolin, adhalin, merosin, dys
ferlin, merosin, emerin, desmin and collagen VI was found, thus pointing
to a sarcoglycanopathy or dystrophinopathy. Heart U/S showed only
mild mitral and tricuspid regurgitation and brain MRI did not reveal any
abnormal findings. The patient’s 14-year-old sister presented with
similar clinical features, albeit milder, and again her brain MRI was
unrevealing. Both parents were unaffected by myopathy or other
neurological ailment and they denied any possibility of consaguinity.
The homozygous c.712A>G change in the CRPPA gene (previously
known as ISPD), leading to the p.Thr238Ala amino acid substitution,
was found by WES, pointing to the diagnosis of LGMD R20. These results
were verified by Sanger sequencing, which also showed the same amino
acid change in the similarly affected sister, again in a homozygous state.
The p.Thr238Ala variant has an exceptionally low frequency in controls
(0.18% ExAC) and is computationally shown to produce a deleterious
effect (CADD score = 24.9).

weakness. Due to her heart problems, an ICD was implanted. Cardiac
and skeletal muscle involvement developed gradually during her third
decade of life. The EMG revealed distinct myopathic features. Family
history was positive for sudden cardiac deaths and dilated cardiomy
opathy (Fig. 2), indicating a possible autosomal dominant inheritance
pattern. Via WES, we identified a heterozygous novel splice site variant
(c.1608+2T>C) in the LMNA gene in this patient, reaching the diagnosis
of laminopathy (formerly LGMD-1B). The variant is predicted to result
in a decreased splicing efficiently, as shown by a MaxEntScan score
decrease of 79% (from 9.82 to 2.06). Also, in silico analysis using
different bioinformatic tools supports the pathogenic effect of the
c.1608+2T>C variant (CADD score = 29.4).
3.14. Patient #14 (MT-TE)
This 17-year-old patient has presented difficulty walking and
frequent falls since the age of 3 years and later inability to walk unas
sisted. In recent years, he is wheel-chair dependent, has swallowing
difficulties and needs assisted ventilation at nights. The patient also had
osteopenia and glucose intolerance. Electrophysiology revealed
myopathic features and serum testing persistently elevated CPK values.
His mother and maternal grandmother have developed muscle weakness
in a more advanced age compared to the patient. Several maternal
family members have been diagnosed with diabetes. Muscle biopsy in
the patient and his affected mother showed signs of mitochondrial
myopathy. As an off-target finding of WES, we identified a hetero
plasmic variant in the MT-TE mitochondrial gene (m.14709T>C) in this
patient. Sanger sequencing confirmed the presence of this variant in the
patient and his affected mother, establishing the diagnosis of mito
chondrial myopathy.

3.11. Patient #11 (LAMA2)
This 39-year-old male had been diagnosed as a “floppy” infant with
generalized muscle weakness and hypotonia, receiving a diagnosis of
congenital myopathy/muscular dystrophy. He walked at the age of five
years but completed elementary and high school. When he was 14 years
old, he underwent Achilles tendon elongation for pes equinus. On clinical
examination, scoliosis, wadding gait, muscle weakness in a limb-girdle
distribution and markedly decreased deep tendon reflexes were
evident. Also, mild cognitive deficits (MOCA score of 24/30) were
noted. Serum CPK levels were persistently elevated. Repeated EMG
studies were suggestive of myopathy. Heart U/S and 24hr ECG recording
were normal. Pulmonary function tests showed FVC at 68% of normal
values and moderate restrictive defects. Muscle biopsy showed normal
immune-reactivity to antibodies against dystrophin (DYS-1, DYS-2, DYS3), albeit mild deficiency of complex I was observed. Brain MRI was
suggestive of leukoencephalopathy. Testing by WES established the
diagnosis
of
LGMD-R23
due
to
the
LAMA2
gene
c.2208+4_2208+19delAGCTTGCAAGAATGTA
and
p.Ile2508fs*4
(c.7521dupT) variants. Both are novel with the former leading to a
splice-site loss, while the latter causing a frameshift in the reading frame
and a truncated product.

3.15. Patient #15 (MYOT)
This 54-year-old man presented with a history of progressive muscle
weakness and atrophy in his shoulders and face of about one-year
duration. Neurological examination revealed proximal weakness in all
four extremities and muscle atrophy in the shoulder girdle and the lower
half of the facial musculature (Fig. 3). Tendon reflexes were brisk in all
four extremities, but plantar responses were flexor. The patient had a
waddling type of gait and could not jump on one leg, perform a squat or
walk on his heels. Electrophysiological testing revealed a myopathic
disorder with face-shoulder-arm distribution. MRI of cervical and lum
bar spine showed cervical and lumbar stenosis due of degenerative
changes. Serum testing showed mildly increased CPK values (375 U/L).
A heart U/S showed only mild aortic valve deficiency. Pulmonary
function testing revealed minor disturbances of expiratory flows and
reduced maximum inspiratory and expiratory pressures and diffusion
lung capacity. The mother of the patient died at the age of 45 years old,
reportedly from acute ischemic stroke, and his son had a cardiac defi
brillator implanted at the age of 14 years old. WES in this patient
identified the heterozygous p.Thr57fs*2 (c.170delC) change in the
MYOT gene, suggesting the diagnosis of myotilinopathy (formerly
LGMD-1A). It is a novel frameshift variant that leads to a very premature
termination of protein translation and strong computational evidence
exists for a damaging effect on the resulting protein (CADD = 33.0),
supporting its pathogenicity.

3.12. Patient #12 (LMNA)
This 39-year-old female patient had a long history of slowly pro
gressive muscle weakness and atrophy in a limb girdle distribution since
her childhood, initially presenting as difficulty in climbing stairs and
running. In the past few years, she was diagnosed with second degree
atrioventricular block and dilated cardiomyopathy and underwent im
plantation of implantable cardioverter defibrillator (ICD). She had
mildly increased CPK values in repeated measurements. Her EMG
showed a myopathic pattern and a deltoid muscle biopsy revealed
dystrophic changes (degeneration / regeneration) with type 1 fiber
predominance. Her family’s history was negative for neurologic disease.
In this patient, we identified the p.Arg249Gln (c.746G>A) heterozygous
LMNA gene variant, establishing the diagnosis of laminopathy (formerly
LGMD-1B). Sanger sequencing confirmed the presence of the p.
Arg249Gln LMNA variant in the patient, and showed absence of this
variant in her parents, raising the possibility of a de novo mutation. This
variant is not present in population databases (rs59332535, no ExAC
frequency)

3.16. Patient #16 (SGCA)
This 11-year-old patient was referred due to increased CPK values
(up to 1,158 U/L) in repeated measurements. He did not show any
symptoms of significant muscle weakness and his growth had been
normal. Muscle biopsy was non-diagnostic, revealing only mild histo
pathological changes. Heart U/S did not show abnormal findings. No
pathogenic changes were found in the DMD gene. By performing WES,
we identified the p.Val247Met (c.739G>A) and p.Arg284Cys

3.13. Patient #13 (LMNA)
This 47-year-old female patient presented with history of ventricular
arrhythmias, second degree atrioventricular block, dilated cardiomy
opathy (diagnosed with both MRI and U/S) and mild proximal muscle
6
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Fig. 2. Family pedigree of patient #13, harboring a heterozygous novel splice site variant (c.1608+2T>C) in the LMNA gene. The proband is indicated by an
arrowhead (III-2) and subjects possibly affected by laminopathy are colored in grey. Subjects II-5, III-1 and III-2 suffered from second degree atrioventricular block
and dilated cardiomyopathy and underwent either a permanent pacemaker or an implantable cardioverter-defibrillator insertion. The symbol for deceased subjects is
marked with a diagonal bar and age of death is placed in the upper right corner.

Fig. 3. Photos of the patient #15 showing muscle atrophy in the shoulder girdle and the lower half of the facial musculature. WES testing identified the p.Thr57fs*2
(c.170delC) change in the MYOT gene, suggesting the diagnosis of myotilinopathy.

(c.850C>T) pathogenic variants in the SGCA gene.

mitochondrial myopathy gene, as an off target result of WES (1 patient;
MT-TE) and in 3 other myopathy genes (4 patients; CAV3, LMNA,
MYOT). In our study, we have identified some novel variants, unique to
the Greek population. Also, most of the known pathogenic variants we
describe have been associated with multiple phenotypes in the litera
ture, and we present here their phenotypic expression in cohort from
Greece.
The diagnostic rate in our cohort (16/24; 66.7%) is considered high
compared to other similar cohorts. In a recent US study, the application
of NGS targeted gene panels resulted in genetic diagnosis in 27% of

4. Discussion
Here we have tested by WES consecutive unselected Greek patients
affected with LGMD and other inherited myopathies and found in 16 of
them causative variants in 14 genes (Table 1). Specifically, we found
pathogenic variants in 6 LGMD genes (6 patients; ANO5, CAPN3, DYSF,
ISPD, LAMA2, SGCA), in 3 metabolic myopathy genes (4 patients; CPT2,
ETFDH, GAA), in 1 congenital myotonia gene (1 patient; CLCN1), in 1
7
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4,656 LGMD patients, with the most common pathogenic variants
identified in the CAPN3, DYSF, FKRP and ANO5 genes [6]. A similar NGS
panel study from Latin America identified a definite genetic cause in
16% of 2,103 LGMD patients [24]. The higher diagnostic rate in our
cohort compared to these LGMD cohorts probably relates to the inclu
sion of muscle disorders, such as metabolic myopathies and congenital
myotonias, that are more prone to genetic diagnosis. Also, WES, that we
used in our study, compared to panel-based NGS techniques, allows the
identification of pathogenic variants in genes not covered in gene
panels, and thus improved diagnostic yield [20].
Patient #1 was found to be compound heterozygote for the p.
Met542fs*11 and p.Phe506fs*6 changes in the ANO5 gene. Pathogenic
variants in the ANO5 gene are causing autosomal recessive Miyoshi
muscular dystrophy type 3, autosomal recessive LGMD type 12 (R12,
formerly 2L), asymptomatic hyperCKaimia, exercise associated
myalgia/myoglobinuria and autosomal dominant gnathodiaphyseal
dysplasia [25,26]. Anoctamin 5, encoded by the ANO5 gene, is a
member of the anoctamins, a family of 10 calcium-activated proteins,
with diverse cellular functions, including Cl- channeling, intracellular
signaling and membrane trafficking and repair [27]. Each of these
proteins has a distinct tissue distribution and physiological function,
with ANO5 mainly expressed in skeletal and cardiac muscle and bone
[25]. The shift in the reading frame caused by both ANO5 variants found
in our patient (p.Met542fs*11 and p.Phe506fs*6) leads to a truncated
protein product, in a gene where loss of function is not well tolerated.
The p.Phe506fs*6 change has been described before in LGMD patients
[27–29]. Specifically, it has been described (as c.1520delT), along with
the intronic splice site variant c.1899–4A>G, in an Italian patient with
onset of proximal upper limb weakness and increased CPK at the age of
50 years [30]. Also, it has been found, concomitantly with another
frameshift change (c.191dupA), in a 39-year-old asymptomatic patient
with increased CPK and skeletal muscle involvement in MRI [31,32].
About the p.Met542fs*11 change, it has been described, as homozygous
c.1627dupA change, in two Italian brothers with LGMD [33].
In patient #2, the p.Tyr537* change and a deletion of exons 2 to 8 in
the CAPN3 gene were identified by WES and MLPA, respectively.
Pathogenic variants in the CAPN3 gene are the cause of the autosomal
recessive LGMD-R1 (formerly known as LGMD-2A) [34] and the less
severe autosomal dominant LGMD-D4 [35,36]. Calpain-3, the protein
encoded by the CAPN3 gene, is the skeletal muscle specific member of
the calpains, a family of Ca2+ dependent cysteine proteases with het
erogeneous function and tissue distribution [34]. Calpain-3 has several
unique properties, including rapid auto-degradation, Na+ dependence
and non-proteolytic functions [37]. Both CAPN3 variants found it our
patient have been described before as pathogenic. In specific, the p.
Tyr537* variant has been found in homozygosity in LGMD patients from
Turkey [38,39] and in compound heterozygosity with 550delA in a
family from Croatia [40]. Likewise, the deletion of exons 2-8 (p.
Glu104_Arg372delfshX11) has been described before in two Bulgarian
patients, again in compound heterozygosity with c.550delA [41].
In patient #3 we found the pathogenic CAV3 variant (c.233C>T, p.
Thr78Met) in the heterozygous state. CAV3 pathogenic variants are
associated with caveolinopathies, that include skeletal muscle pathol
ogies such as LGMD type 1C (not included in the new LGMD classifi
cation), rippling muscle disease, distal myopathy, and isolated
hyperCKemia, as well as cardiac abnormalities such as long QT syn
drome, sudden infant death syndrome and hypertrophic cardiomyopa
thy[42]. Caveolinopathies present with heterogeneous features such as
exercise intolerance, myalgia, rhabdomyolysis, and rippling and
percussion-induced muscle contractions [43]. Caveolin-3, the protein
encoded by CAV3, forms flask-shaped invaginations on the cytoplasmic
surface of the sarcolemma, termed caveolae. These caveolae have an
essential role in maintenance of sarcolemmal integrity, vesicular traf
ficking and signal transduction [44]. The p.Thr78Met CAV3 variant
found in our patient has been repeatedly described in the literature as
pathogenic, associated with many different phenotypes [43,45–54].

This variant is part of the central hydrophobic transmembrane domain
of the caveolin 3 and has been shown to affect its function. In spite of the
association of p.Thr78Met CAV3 with both skeletal and cardiac muscle
pathologies, its functional role regarding cardiac diseases has been a
matter of controversy. In particular, it has been characterized as a
variant of unknown or benign significance after it has been found in
healthy individuals with frequencies comparable to cases with long QT
syndrome [55,56]. Even though this variant has been found also in the
patient’s asymptomatic father, we ascribe this to a possible concerted
action with another yet unidentified variant that predisposes to the
specific phenotypic characteristics, as it has been previously suggested
for the role of p.Thr78Met CAV3 in cardiac diseases [57].
In patient #4 and her similarly affected sister we reached the diag
nosis of Myotonia Congenita due to the exonic p.Phe167Leu (c.501C>G)
and splice site c.1471+1G>A variants in the CLCN1 gene. Pathogenic
variants in the CLCN1 gene are the cause of autosomal dominant
(Thomsen) and autosomal recessive (Becker) Myotonia Congenita, an
inherited skeletal muscle channelopathy [58,59]. Chloride channels,
encoded by the CLCN1 gene, are important for the muscle fiber repo
larization and the stability of the sarcollemal resting potential [60]. Both
variants found in our patient and her sister have been described before
in the literature [61–65].
In patients #5 and #6, as well as the affected sister of patient #5, all
presenting with episodes of acute rhabdomyolysis, we found the p.
Ser113Leu (c.338C>T) CPT2 gene variant in homozygosity. CPT2 gene
variants are the cause of CPT II deficiency, one of the most common
mitochondrial fatty acid oxidation disorders [66]. CPT II deficiency
manifests as recurrent acute rhabdomyolysis associated with metabolic
decompensation and intermittent myopathic symptoms, both usually
triggered by exercise or infection [67]. The carnitine palmitoyl
transferase (CPT) system mediates long chain fatty acid translocation
across the mitochondrial membrane from the cytosol to the mitochon
drial matrix, where these fatty acids are used for energy production
through the β-oxidation process [66]. The CPT-2 protein, encoded by the
CPT2 gene, is embedded in the inner mitochondrial membrane and
forms part of the CPT system [68]. Given that the p.Ser113Leu CPT2
gene variant is the most frequently identified CPT II pathogenic variant
in large series of Caucasian patients, with most of the patients reported
to date being homozygous, and since our patients were apparently un
related, the possibility of a founder effect seems unlikely [67,69–73].
For both patients 5 and 6, although their clinical picture was high sus
picious for beta-oxidation defect, especially CPT II deficiency, repeated
testing for organic acids and carnitine esters yielded results within
normal range, even at times of significantly elevated CPK levels. Thus,
given that other diagnostic modalities proved unsuccessful, genetic
diagnosis was important to avoid serious and even life-threatening
complications, such as acute renal failure by timely intervening with
high-glucose fluids, correction of metabolic acidosis and early dialysis.
In patient #7, an 18-year-old male with progressively deteriorating
leg pain and cramps, myopathic EMG features and increased CPK values,
we identified the pathogenic c.907-1G>A and p.Ala927fs*21
(c.2779delG) DYSF gene changes in compound heterozygosity. Patho
genic variants in the DYSF gene cause LGMD-R2 (formerly 2B), Miyoshi
muscular dystrophy type 1 and distal myopathy with anterior tibial
onset, collectively called dysferlinopathies [74,75]. Dysferlin, encoded
by the DYSF gene, regulates vesicle fusion contributing patching of
sarcolemmal defects [76]. Concerning the two DYSF variants found in
our patient, the novel c.907-1G>A change is absent from controls and is
predicted to be deleterious probably by affecting splicing, while the p.
Ala927fs*21 DYSF change causes frameshift and premature termination
of the protein translation. Furthermore, it has been described as path
ogenic in myopathy patients in Iran, Turkey, South Spain and more
importantly in Israel, in several members of the community of Jews
originating from Caucasus, where a founder effect and a 4% carrier
frequency has been identified [77–82].
In patient #8, WES established the diagnosis of metabolic myopathy
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due to the p.Pro483Leu (c.1448C>T) and p.Arg559* (c.1675C>T) var
iants in the ETFDH gene. Variants in the ETFDH gene are one of the
causes of Glutaric acidemia type II (Multiple acyl-CoA dehydrogenase
deficiency -MADD), specifically type IIC. The two other causes of MADD
are pathogenic variants in the ETFA and ETFB genes. The proteins
encoded by the ETFA, ETFB and ETFDH genes, electron transfer flavo
protein (ETF) A and ETF-B and EFT Dehydrogenase, respectively, are
involved in the transfer of electrons to the mitochondrial respiratory
chain by flavoproteins. MADD’s clinical manifestations range from a
neonatal form characterized by acidosis, hypoglycemia, cardiomyopa
thy and encephalopathy, to an adult-onset form with progressive muscle
weakness, exercise intolerance, and episodes of vomiting, hypoglyce
mia, and metabolic acidosis. MADD is considered one of the curable
myopathies, with riboflavin administration having excellent results in a
sizable proportion of patients [83], as was the case in our patient. The p.
Pro483Leu ETFDH change found in our patient has been described
initially in a 13-year-old Turkish girl, born to consanguineous parents
and presenting muscle weakness with inability to walk, myalgias and
increased CPK. The patient showed full recovery following administra
tion of riboflavin [84]. Subsequently, the p.Pro483Leu variant has been
reported as pathogenic, but responsive to riboflavin, several other times
[85–88]. Concerning the second ETFDH variant (p.Arg559*) found in
our patient, this causes premature translation termination resulting in a
truncated protein and has also been described before as pathogenic [89].
In patient #9, we detected trans heterozygosity of the pathogenic
variants c.-32-13T>G and p.Tyr292Cys (c.875A>G) in the GAA gene.
Variants in the GAA gene are the cause of Pompe’s disease (formerly
LGMD-2V), the clinical spectrum of which ranges from severe infantile
forms to milder late-onset forms, with the diagnosis of the latter being
challenging [90,91]. Our patient with late-onset Pompe disease was
finally diagnosed by WES following a 10-year delay, despite inconclu
sive initial muscle biopsy and biochemical studies. The role of WES in
detecting pathogenic GAA variants has been recently emphasized [92],
despite initial shortcomings probably due to limitations of earlier WES
techniques [93]. Pompe’s disease is characterized by lysosomal
glycogen accumulation, due to acid alpha-glucosidase (GAA) deficiency,
progressively affecting skeletal, respiratory and heart muscles [94].
About the c.-32-13T>G change of our patient, it has been repeatedly
described, being the most common in cohorts of patients with late onset
Pompe’s disease, with a frequency up to 87.5% [6,19,91,92,95–98]. The
c.-32-13T>G change has been shown to affect splicing, leading to
omission of exon 2, where the start codon is located [95,99]. Thus, it is
established as pathogenic, despite the low computational evidence
supporting its pathogenicity (CADD score <10). About the p.Tyr292Cys
change, it has also been described in the literature in cases of juvenile
and other forms of glycogenosis [97,100–102]. It is located in a muta
tional hotspot, in a critical domain of the GAA enzyme, whereas func
tional studies strongly support its pathogenicity [103,104]. Of note,
both variants of our patient have been found in compound heterozy
gosity in a patient from Spain, with approximately the same age at
disease onset as our patient (60 years) [96].
About patient #10 and her similarly affected sister, the p.Thr238Ala
(c.712A>G) change in exon 4 of the CRPPA (ISPD) gene was found in
homozygous state, leading to the diagnosis of LGMD type R20. CRPPA
gene pathogenic variants have been reported to cause a spectrum of
phenotypes ranging from congenital muscular dystrophy with cerebral
and ocular involvement (Walker-Warburg syndrome), through mild
muscle weakness and subtentorial brain involvement, to mild adult
onset LGMD phenotype without CNS involvement [105–109]. CNS
involvement was unlikely in our patients, since no cognitive deficits
were found, and brain MRI did not show any abnormalities. CRPPA
variants are a rare cause of LGMD; in an Italian study, they were found in
less than 1% of the entire LGMD cohort [110]. The D-ribitol-5-phosphate
cytidylyltransferase protein encoded by the CRPPA gene contributes to
the glycosylation of dystroglycan in the cytosol [109]. Dystroglycan is a
major adhesion complex, composed of one α- and one β-subunit, that

connects the subsarcolemmal actin cytoskeleton to the extracellular
matrix, thus providing stability to skeletal muscles [111]. CRPPA mu
tations disrupt α-dystroglycan glycosylation, leading to reduced binding
capacity of ECM ligands and thus compromising myocyte integrity and
function [18,109]. The p.Thr238Ala (c.712A>G) variant found in ho
mozygosity in our patient and her sister is located in a mutational hot
spot and in a well-established CRPPA functional domain (Glyco_
tranf_GTA_type) where no benign variation has been found. It is note
worthy that a similar change (c.713C>T, leading also to the p.Thr238Ile
amino acid substitution) in compound heterozygosity with a nonsense
variant (p.Arg86*) in the CRPPA gene has been reported to result in
severe Cobblestone Lissencephaly [112].
In patient #11, we found the c.2208+4_2208+19delAGCTTGC
AAGAATGTA and p.Ile2508fs*4 (c.7521dupT) LAMA2 gene variants.
Pathogenic variants in the LAMA2 gene are the cause of congenital
muscular dystrophy type 1A (MDC1A) and LGMD-R23. Again, as in
other genes, all the myopathic phenotypes caused by LAMA2 gene
variants have been reclassified under the comprehensive name “LAMA2related muscular dystrophies” [113]. Brain MRI in our patient showed
diffuse cerebral hemispheric white matter abnormalities; this is not
uncommon in congenital muscular dystrophies [114].The LAMA2 gene
encodes for the laminin a2 chain (also known as merosin) of the heter
otrimeric laminin-211 complex that stably connects the sarcolemma to
the extracellular matrix. The c.7521dupT (p.I2508fs*4) LAMA2 variant
in our patient has not been described before in the literature; however, it
is considered pathogenic since it is a frameshift variant that leads to a
truncated protein, in a gene where loss of function is a known patho
genetic mechanism. The second LAMA2 variant found in our patient
(c.2208+4_2208+19delAGCTTGCAAGAATGTA) leads to a splice-site
loss, and as such it is also considered pathogenic.
In two female patients (#12, #13) with cardiomyopathy and skeletal
myopathy, we report the p.Arg249Gln (c.746G>A) and the splice-site
c.1608+2T>C LMNA gene variants, respectively. LMNA gene patho
genic variants are implicated in laminopathies, a group of disorders
manifesting as heart disease, Emery-Dreifuss, congenital and limb-girdle
muscular dystrophies, lipodystrophy, metabolic disorders, CharcotMarie-Tooth disease and premature aging syndromes [115,116]. Heart
involvement, characterized by conduction system defects, arrhythmias,
dilated cardiomyopathy, arrhythmogenic right ventricular cardiomy
opathy, heart failure and sudden cardiac death, is highly prevalent
[117–119]. Lamins A and C, encoded by the LMNA gene, are major
structural components of the nuclear lamina, a fibrillar network that
stabilizes the nuclear envelope [120]. Additionally, lamins are involved
in multiple cellular processes, such as chromatin organization, DNA
replication, gene and cell-cycle regulation and nucleo-cytoskeletal
coupling [118]. Even though the frequency of the p.Arg249Gln LMNA
gene variant found in our patient #12 is probably extremely low, it has
already been extensively described in the literature as pathogenic, being
reported in multiple unrelated individuals affected with Emery-Dreifuss
muscular dystrophy and a single individual affected with LGMD
[15,16,121–127]. The c.1608+2T>C LMNA variant found in our patient
#13 is predicted to affect splicing. The strongest neighboring alternative
splice site lies 72 bases upstream from the exon/intron boundary and
this is predicted to result in an in-frame deletion. There have been
several splice site variants in the LMNA gene that are described as
pathogenic, including the c.1608+5G>C change[128], just 3 nucleo
tides downstream of the c.1608+2T>C variant of our patient. Finally,
this variant is extremely rare in public variant databases.
In patient #14, we identified a heteroplasmic variant in the MT-TE
mitochondrial gene (m.14709T>C), as an off-target finding of WES. The
MT-TE gene encodes for the mitochondrial t-RNA for glutamate, and as
such, pathogenic variants in this gene are expected to disrupt intra
mitochondrial protein synthesis. The m.14709T>C MT-TE gene variant
is reported as pathogenic in both the ClinVar and MitoMap databases
and has been associated with several syndromes, including 1) mito
chondrial myopathy with diabetes mellitus, 2) maternally transmitted
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diabetes- deafness syndrome, 3) juvenile myopathy, encephalopathy,
lactic acidosis and stroke. There have been numerous publications
describing large families in which the m.14709T>C MT-TE gene variant
segregates with diabetes mellitus and myopathy, independently,
concurrently or sequentially [129–139], as was the case in our patient’s
family. The presence in our patient #14’s extended family of members
with myopathy, diabetes or both is an interesting finding, and indicates
that physician should have raised awareness in similar clinical scenarios
to consider a mitochondrial disorder in their differential diagnosis.
Interestingly, there is still debate about the exact pathophysiological
mechanism of the phenotype associated with the m.14709T>C variant
[140].
In the case of patient #15, with progressive quadriparesis and
proximal limb and lower face atrophy, we found the p.Thr57fs*2 MYOT
variant. Variants in the MYOT gene have been associated with various
autosomal dominant disease phenotypes (myotilinopathies), that
include the former LGMD-1A subtype and a subgroup of the myofibrillar
myopathies [141–145]. Myotilin, the 498 amino acid long protein
encoded by the MYOT gene, is a sarcomeric Z-disk component that acts
together with a-actinin and filamin C to cross link actin and support the
integrity of the contracting myocyte [143]. The p.Thr57fs*2 (c.170delC)
MYOT variant found in our patient has not been previously described in
the literature. However, the predicted effect on protein translation, in a
gene where loss of function usually leads to disease, combined with the
high CADD score, justifies its pathogenicity. Interestingly, an amino acid
substitution at the same residue (p.Thr57Ile) has been found as the cause
of LGMD-1A in a large North American pedigree of German descent
[146].
In patient #16, with persistent hyperCKemia, by performing WES we
identified the p.Val247Met (c.739G>A) and p.Arg284Cys (c.850C>T)
pathogenic variants in the SGCA gene. Variants in the SGCA gene have
been associated with autosomal recessive LGMD-R3, formerly known as
LGMD-2D [147]. The protein encoded by the SGCA gene, α-sarcoglycan
(also known as adhalin), is part of the multi-protein Dystrophin Glyco
protein Complex (DGC) that spans the sarcolemma and links cytoskel
etal actin to the extracellular matrix [148]. Other components of the
DGC include dystrophin, syntrophins and dystroglycans [149]. This
complex has an important role in maintaining the structural integrity of
myocytes and the stability of the neuromuscular junction [148,150].
The p.Val247Met SGCA change found in our patient is considered the
second most common SGCA variant associated with LGMD and hyper
CKemia, having been described repeatedly [151–155]. Similarly, there
are several reports describing LGMD patients harboring the second
SGCA variant (p.Arg284Cys) found in our patient [6,152,155–160].

known pathogenic variants with multiple phenotypic presentations.
Also, our results hint to the nearly impossible task of phenotypically and
genotypically categorizing myopathies according to existing classifica
tion systems. This failure, in conjunction with the expected availability
of gene therapies, calls for a new gene-based approach for classifying
inherited myopathies.
Submission of data to a genetic database
All variants described herein have been uploaded to the LOVD
database (https://www.lovd.nl/).
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[80] C. Paradas, L. González-Quereda, N. De Luna, E. Gallardo, I. García-Consuegra,
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et al., Milder forms of α-sarcoglicanopathies diagnosed in adulthood by NGS
analysis, J. Neurol. Sci. 394 (2018) 63–67.
[160] L. Wu, L. Brady, J. Shoffner, M.A. Tarnopolsky, Next-generation sequencing to
diagnose muscular dystrophy, rhabdomyolysis, and HyperCKemia, Can. J. Neurol.
Sci. 45 (3) (2018) 262–268.
[161] J.R. Mendell, L.G. Chicoine, S.A. Al-Zaidy, Z. Sahenk, K. Lehman, L. Lowes, et al.,
Gene delivery for limb-girdle muscular dystrophy type 2D by isolated limb
infusion, Hum. Gene Ther. 30 (7) (2019) 794–801.

[128] A. Muchir, G. Bonne, A.J. van der Kooi, M. van Meegen, F. Baas, P.A. Bolhuis, et
al., Identification of mutations in the gene encoding lamins A/C in autosomal
dominant limb girdle muscular dystrophy with atrioventricular conduction
disturbances (LGMD1B), Hum. Mol. Genet. 9 (9) (2000) 1453–1459.
[129] H. Hao, E. Bonilla, G. Manfredi, S. DiMauro, C.T. Moraes, Segregation patterns of
a novel mutation in the mitochondrial tRNA glutamic acid gene associated with
myopathy and diabetes mellitus, Am. J. Hum. Genet. 56 (5) (1995) 1017–1025.
[130] M. Mancuso, S. Ferraris, Y. Nishigaki, G. Azan, A. Mauro, P. Sammarco, et al.,
Congenital or late-onset myopathy in patients with the T14709C mtDNA
mutation, J. Neurol. Sci. 228 (1) (2005) 93–97.
[131] M. Damore, P. Speiser, A. Slonim, M. New, S. Shanske, W. Xia, et al., Early onset
of diabetes mellitus associated with the mitochondrial DNA T14709C point
mutation: patient report and literature review, J. Pediatr. Endocrinol. Metab. 12
(2) (1999) 207–213.
[132] M.G. Hanna, I. Nelson, M.G. Sweeney, J.M. Cooper, P.J. Watkins, J.A. MorganHughes, et al., Congenital encephalomyopathy and adult-onset myopathy and
diabetes mellitus: different phenotypic associations of a new heteroplasmic
mtDNA tRNA glutamic acid mutation, Am. J. Hum. Genet. 56 (5) (1995)
1026–1033.
[133] R. McFarland, A.M. Schaefer, J.L. Gardner, S. Lynn, C.M. Hayes, M.J. Barron, et
al., Familial myopathy: new insights into the T14709C mitochondrial tRNA
mutation, Ann. Neurol. 55 (4) (2004) 478–484.
[134] B. Vialettes, V. Paquis-Flucklinger, J. Pelissier, D. Bendahan, H. Narbonne,
P. Silvestre-Aillaud, et al., Phenotypic expression of diabetes secondary to a
T14709C mutation of mitochondrial DNA. Comparison with MIDD syndrome
(A3243G mutation): a case report, Diabetes Care 20 (11) (1997) 1731–1737.
[135] L. Rigoli, F. Prisco, R. Caruso, D. Lafusco, G. Ursomanno, D. Zuccarello, et al.,
Association of the T14709C mutation of mitochondrial DNA with maternally
inherited diabetes mellitus and/or deafness in an Italian family, Diabet. Med. 18
(4) (2001) 334–336.
[136] G.S. Gorman, A.M. Schaefer, Y. Ng, N. Gomez, E.L. Blakely, C.L. Alston, et al.,
Prevalence of nuclear and mitochondrial DNA mutations related to adult
mitochondrial disease, Ann. Neurol. 77 (5) (2015) 753–759.
[137] N.Z. Lax, P.D. Hepplewhite, A.K. Reeve, V. Nesbitt, R. McFarland, E. Jaros, et al.,
Cerebellar ataxia in patients with mitochondrial DNA disease: a molecular
clinicopathological study, J. Neuropathol. Exp. Neurol. 71 (2) (2012) 148–161.
[138] N.Z. Lax, I.S. Pienaar, A.K. Reeve, P.D. Hepplewhite, E. Jaros, R.W. Taylor, et al.,
Microangiopathy in the cerebellum of patients with mitochondrial DNA disease,
Brain 135 (6) (2012) 1736–1750.
[139] N. Mezghani, E. Mkaouar-Rebai, M. Mnif, N. Charfi, N. Rekik, S. Youssef, et al.,
The heteroplasmic m.14709T>C mutation in the tRNAGlu gene in two Tunisian
families with mitochondrial diabetes, J. Diabetes Complicat. 24 (4) (2010)
270–277.
[140] D. Perucca-Lostanlen, R.W. Taylor, H. Narbonne, B. Mousson de Camaret, C.
M. Hayes, A. Saunieres, et al., Molecular and functional effects of the T14709C
point mutation in the mitochondrial DNA of a patient with maternally inherited
diabetes and deafness, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1588 (3)
(2002) 210–216.
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